$966 Billion is the total value of Casdin Capital, LLC's 33 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVTA | INVITAE CORP | $73,965,737,000 | -18.0% | 3,838,388 | 0.0% | 7.66% | -9.3% | |
| CDXS | CODEXIS INC | $69,586,892,000 | -19.6% | 5,073,780 | 0.0% | 7.20% | -11.1% | |
| BPMC | BLUEPRINT MEDICINES CORP | $69,061,800,000 | -22.1% | 940,000 | 0.0% | 7.15% | -13.9% | |
| SAGE | SAGE THERAPEUTICS INC | $56,116,000,000 | -23.4% | 400,000 | 0.0% | 5.81% | -15.3% | |
| BLFS | BIOLIFE SOLUTIONS INC | $40,374,993,000 | +2.5% | 2,428,571 | 0.0% | 4.18% | +13.3% | |
| FATE | FATE THERAPEUTICS INC | $39,601,500,000 | -23.5% | 2,550,000 | 0.0% | 4.10% | -15.4% | |
| GNMK | GENMARK DIAGNOSTICS INC | $20,391,900,000 | -6.6% | 3,365,000 | 0.0% | 2.11% | +3.2% | |
| VYGR | VOYAGER THERAPEUTICS INC | $19,414,171,000 | -36.8% | 1,128,075 | 0.0% | 2.01% | -30.1% | |
| ILMN | ILLUMINA INC | $18,253,200,000 | -17.4% | 60,000 | 0.0% | 1.89% | -8.7% | |
| GRTS | GRITSTONE ONCOLOGY INC | $15,283,950,000 | -22.5% | 1,770,000 | 0.0% | 1.58% | -14.3% | |
| GBT | GLOBAL BLOOD THERAPEUTICS IN | $14,556,000,000 | -7.8% | 300,000 | 0.0% | 1.51% | +2.0% | |
| ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $14,310,562,000 | -28.8% | 463,125 | 0.0% | 1.48% | -21.3% | |
| CNST | CONSTELLATION PHARMCETICLS I | $9,844,782,000 | -47.4% | 1,523,960 | 0.0% | 1.02% | -41.8% | |
| TWST | TWIST BIOSCIENCE CORP | $7,164,000,000 | -17.7% | 300,000 | 0.0% | 0.74% | -9.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2020-01-03
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-28 |
| 4 | 2024-05-28 |
| 4 | 2024-05-22 |
| SC 13D/A | 2024-05-22 |
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-15 |
| 4 | 2024-05-02 |
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.